Tenvie Therapeutics develops engineered small molecules to target and modulate specific pathways involved in neurological diseases. This approach aims to improve treatment efficacy and patient outcomes in conditions such as Alzheimer's and Parkinson's disease.
Funding
$200M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
MCFounders
Product
Problem
Many neurological, cardiometabolic, and ophthalmic diseases lack effective treatments, leaving significant unmet needs for patients and caregivers. Current therapeutic approaches often fail to adequately address the complex underlying drivers of these conditions, such as inflammation, metabolic dysfunction, and impaired lysosomal function. This results in limited therapeutic benefits and a lack of durable solutions for patients suffering from these debilitating diseases.
Solution
Tenvie Therapeutics is developing a pipeline of small molecule therapeutics designed to address the key drivers of neurological, cardiometabolic, and ophthalmic diseases. Their approach focuses on creating highly brain-penetrant and peripherally restricted small molecules that can resolve inflammation, rescue metabolic dysfunction, and restore lysosomal function. By optimizing molecular delivery properties, Tenvie aims to maximize patient impact across a broad array of diseases. Their portfolio includes programs targeting neuroprotective pathways, such as TRPML1 and TMEM175, as well as advanced programs like an NLRP3 inhibitor and an allosteric SARM1 inhibitor, both in the IND-enabling stage.
Target Audience
Tenvie's therapies target patients and caregivers affected by neurological, cardiometabolic, and ophthalmic diseases, particularly those with limited or no effective treatment options.
Features
- Development of wholly owned, highly CNS-penetrant small molecules
- Precision-designed peripherally-restricted small molecules for targeted action
- Programs focused on resolving inflammation, rescuing metabolic dysfunction, and restoring lysosomal function
- Advanced programs include an NLRP3 inhibitor and an allosteric SARM1 inhibitor in IND-enabling stage
- Pipeline includes programs focused on neuroprotective pathways, including TRPML1 and TMEM175
- Utilizes expertise in optimizing critical molecular delivery properties